We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Draft Guidance Outlines Testing for Generic Abuse-Deterrent Opioids
FDA Draft Guidance Outlines Testing for Generic Abuse-Deterrent Opioids
In its second move this week to tackle the growing opioid epidemic, the FDA is outlining what tests sponsors of abuse-deterrent generic opioids should submit.